Owned by Vietnam’s wealthiest man, VinFast is more immune to not making a profit. On Thursday, the company reported it lost ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

US stocks plunged following Trump's comments, with the S&P 500 ( ^GSPC) closing Monday's session down 2.4%, the tech-focused Nasdaq ( ^IXIC) sliding 2.6% and the Dow Jones Industrial Average ( ^DJI) ...

The scale of President Donald Trump’s tariffs has exceeded even the most bearish forecasts — and could impact these five ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

When I started taking a GLP-1 medication in October, I knew it would probably change a few things—our weekly dinner plan, how ...

The results bring Eli Lilly’s pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

14%). The company has faced failure to meet the weight-loss target with its CagriSema injection treatment twice, which caused Novo Nordisk a huge setback. Intense rivalry in the obesity sector ...